GCVRZ - Sanofi

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
0.8700
-0.0014 (-0.16%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.8714
Open0.8750
Bid0.8700 x 1800
Ask0.8701 x 1800
Day's Range0.8690 - 0.8760
52 Week Range0.3400 - 0.8800
Volume230,791
Avg. Volume197,626
Market Cap1.085B
Beta (5Y Monthly)0.46
PE Ratio (TTM)0.22
EPS (TTM)3.8800
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Biotech outlook as companies race to develop coronavirus vaccine
    Yahoo Finance Video

    Biotech outlook as companies race to develop coronavirus vaccine

    Biotech companies are racing to develop vaccines and treatments as the coronavirus outbreak continues to spread. Yahoo Finance’s Anjalee Khemlani joins Dan Roberts, Julia La Roche and NYU Marketing Professor Scott Galloway on YFi PM to discuss the latest developments.

  • These stocks are poised to benefit as coronavirus roils markets
    Yahoo Finance

    These stocks are poised to benefit as coronavirus roils markets

    The historic stock market rout may have a few hidden winners as the coronavirus crisis ricochets across the globe.

  • PR Newswire

    Sanofi US reaches settlement agreement to resolve allegations related to patient assistance

    Sanofi U.S. today announced that it has reached an $11.85 million settlement agreement with the federal government to resolve an investigation relating to certain financial donations made in 2015 and 2016 to an independent charity patient assistance foundation that aided patients living with multiple sclerosis.

  • Sanofi to pay $11.9 million to resolve U.S. drug charity kickback probe
    Reuters

    Sanofi to pay $11.9 million to resolve U.S. drug charity kickback probe

    Sanofi SA has agreed to pay $11.85 million to resolve U.S. allegations that it used a charity that helps cover Medicare patients' out-of-pocket drug costs as a means to pay them kickbacks to use a high-priced multiple sclerosis drug. The deal, announced by the U.S. Justice Department on Friday, was the latest to result from an industry-wide probe of drugmakers' financial support of patient assistance charities that has resulted in more than $865 million in settlements. The government said Sanofi provided payments to one such charity, The Assistance Fund, not with a charitable purpose in mind but instead to use it as a means to cover the co-pay obligations of Medicare patients using the MS drug Lemtrada.

  • Pharma Stock Roundup: FDA Updates From LLY, GSK, NVS, SNY to Spin-Off API Unit
    Zacks

    Pharma Stock Roundup: FDA Updates From LLY, GSK, NVS, SNY to Spin-Off API Unit

    FDA accepts Glaxo (GSK) and Novartis' (NVS) sBLA. FDA gives approval to Lilly's (LLY) Trulicity for cardiovascular indication.

  • Sanofi Plans Spin-Off of API Unit Into a European Company
    Zacks

    Sanofi Plans Spin-Off of API Unit Into a European Company

    Sanofi (SNY) plans to combine its API commercial activities with six of its European API production sites and spin-off the same into an independent European API company.

  • France's Sanofi to carve out active drug ingredients business
    Reuters

    France's Sanofi to carve out active drug ingredients business

    Sanofi plans to create a standalone company dedicated to making active pharmaceutical ingredients (API), components that are biologically active in a drug, and will decide whether to list it on Euronext Paris by 2022. The French drugmaker on Monday said it would create the business on the back of the combination of its API commercial and development activities with six of its European API production sites in Italy, Germany, Britain, France and Hungary. Europe's pharmaceutical sector is highly dependent on raw materials and active ingredients from Asia, buying products from companies mostly based in China and India.

  • Reuters

    Drug pricing review group signs deal with Aetion for patient data

    The Institute for Clinical and Economic Review (ICER), a small but influential Boston-based research group, has signed a deal with private technology company Aetion to help it use patient health data in its reports on whether individual drugs are priced properly. Large national regulators, including the U.S. Food and Drug Administration and United Kingdom's National Institute for Health and Care Excellence (NICE), are considering increasing the use of data gathered outside of clinical trials on the effectiveness of treatments, often referred to as real-world data. The FDA is running a pilot project using Aetion's database of insurance claims to replicate clinical trial results, as part of a requirement to comply with healthcare legislation called the 21st Century Cures Act.

  • Financial Times

    Sanofi to spin off drug ingredient business by 2022

    The drugmaker plans to float a 70 per cent stake in the new standalone company on the Paris stock exchange, creating what it called a “new industry champion” that would help Europe ensure adequate supply of pharmaceutical ingredients and prevent drug shortages.

  • Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval
    Zacks

    Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval

    AstraZeneca's (AZN) Q4 results were disappointing. European Commission approves Novartis (NVS) and Pfizer's (PFE) new drugs.

  • Oscar Health unveils program for lower drug prices, including insulin
    Yahoo Finance

    Oscar Health unveils program for lower drug prices, including insulin

    Oscar Health is offering prescription drugs at rock-bottom prices, following the lead of other health care players responding to the public’s demand for lower costs.

  • Baxter's Latest Acquisition to Boost Advanced Surgery Arm
    Zacks

    Baxter's Latest Acquisition to Boost Advanced Surgery Arm

    Baxter's (BAX) Advanced Surgery arm boasts of a wide spectrum of products.

  • Sanofi, J&J Join Forces With BARDA for Coronavirus Vaccine
    Zacks

    Sanofi, J&J Join Forces With BARDA for Coronavirus Vaccine

    Sanofi (SNY) and J&J (JNJ) sign deals with BARDA, part of U.S. Department of Health and Human Services, for accelerated development of a vaccine for the newly found coronavirus.

  • TheStreet.com

    Sanofi Joins Race for Coronavirus Vaccine as Death Toll Mounts

    Sanofi will work with a division of the U.S. Health and Human Services Department, with plans to revive work on an advanced prevaccine drug that more than a decade ago it started to develop to combat SARS.

  • Reuters

    Sanofi partners with U.S. agency to develop coronavirus vaccine

    Sanofi said on Tuesday it was working with the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Health Department to develop a vaccine against the new coronavirus from China. The French drugmaker said it intended to further investigate an advanced pre-clinical vaccine candidate previously developed against the SARS virus in the early 2000s, which it believes could protect against the latest coronavirus. Johnson & Johnson said last week it was collaborating with BARDA to speed up development of a coronavirus vaccine.

  • PR Newswire

    Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine

    Sanofi (NASDAQ: SNY; EURONEXT: SAN) Pasteur, the vaccines global business unit of Sanofi, will leverage previous development work for a SARS vaccine which may unlock a fast path forward for developing a COVID-19 vaccine. Sanofi will collaborate with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response, expanding the company's long-standing partnership with BARDA.

  • Is Sanofi (SNY) Stock Undervalued Right Now?
    Zacks

    Is Sanofi (SNY) Stock Undervalued Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • SNY vs. NVO: Which Stock Should Value Investors Buy Now?
    Zacks

    SNY vs. NVO: Which Stock Should Value Investors Buy Now?

    SNY vs. NVO: Which Stock Is the Better Value Option?

  • The No. 1 Biotech Stock Just Squashed Earnings Views — Here's Why
    Investor's Business Daily

    The No. 1 Biotech Stock Just Squashed Earnings Views — Here's Why

    Regeneron profit was better than expected for the fourth quarter. Sales also beat. But shares dipped Friday. The company said it will provide 2020 guidance by the end of the first quarter.

  • French drugmaker Sanofi working on coronavirus initiative
    Reuters

    French drugmaker Sanofi working on coronavirus initiative

    French drugmaker Sanofi will announce a new coronavirus initiative within the next two weeks, its chief executive said on Thursday, adding that it wants to present something concrete and not add to "fantasies". "We have seen a flurry of activities from other companies," CEO Paul Hudson told a news conference after Sanofi published 2019 results on Thursday. Hudson declined to give further details.

  • Drugmaker Sanofi expects further profit growth from narrowed focus
    Reuters

    Drugmaker Sanofi expects further profit growth from narrowed focus

    French drugmaker Sanofi on Thursday forecast further profit growth for 2020 even as it drops some research in areas such as diabetes in a shake-up to narrow its focus on blockbuster treatments including eczema medicine Dupixent. Sanofi, long viewed as a laggard in the pharmaceutical sector, has changed its chief executive, its chief financial officer and head of research over the past two years and is hoping to shine again thanks to the pipeline shake-up and cost cuts. EPS growth reached 6.8% in 2019 as net income rose 7% to 7.5 billion euros ($8.25 billion).

  • Sanofi delivers strong 2019 business EPS growth of 6.8% at CER
    PR Newswire

    Sanofi delivers strong 2019 business EPS growth of 6.8% at CER

    Sanofi (NASDAQ: SNY; EURONEXT: SAN)